Comparative Pharmacology
Head-to-head clinical analysis: MD 76 versus RENOGRAFIN 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 76 versus RENOGRAFIN 76.
MD-76 vs RENOGRAFIN-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-76 is a contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast between vascular structures and surrounding tissues. It distributes in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Radiopaque contrast agent that attenuates X-rays by absorbing them due to its high iodine content, allowing visualization of vascular structures and organs during radiographic procedures.
IV: 50-100 mL per dose, administered as a bolus or infusion, not to exceed 3 mL/kg total dose.
Intravenous administration of 50-100 mL (14.1-28.2 g iodine) as a single dose for angiography; dose varies by procedure and patient size.
None Documented
None Documented
Terminal half-life: 1.5–2 hours; prolonged in renal impairment (up to 20 hours in anuria); clinical context: allows rapid elimination, suitable for diagnostic imaging
Terminal elimination half-life: 1–2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min)
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<5%)
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent